[1]汪晓凤,邵和军.慢性乙型肝炎抗病毒治疗进展[J].医学信息,2019,(04):39-43.[doi:10.3969/j.issn.1006-1959.2019.04.015]
 WANG Xiao-feng,SHAO He-jun.Progress in Antiviral Therapy for Chronic Hepatitis B[J].Medical Information,2019,(04):39-43.[doi:10.3969/j.issn.1006-1959.2019.04.015]
点击复制

慢性乙型肝炎抗病毒治疗进展()
分享到:

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
期数:
2019年04期
页码:
39-43
栏目:
综述
出版日期:
2019-02-15

文章信息/Info

Title:
Progress in Antiviral Therapy for Chronic Hepatitis B
文章编号:
1006-1959(2019)04-0039-05
作者:
汪晓凤邵和军
(贵州省人民医院感染科,贵州 贵阳 550002)
Author(s):
WANG Xiao-fengSHAO He-jun
(Department of Infectious Diseases,Guizhou Provincial People's Hospital,Guiyang 550002,Guizhou,China)
关键词:
慢性乙型肝炎抗病毒治疗干扰素核苷酸(类)似物免疫调节
Keywords:
Chronic hepatitis BAntiviral therapyInterferonNucleotide (like) analogImmune regulation
分类号:
R512.62
DOI:
10.3969/j.issn.1006-1959.2019.04.015
文献标志码:
A
摘要:
慢性乙型肝炎的抗病毒治疗仍是国内外所面临的一大难题,近年来虽已取得显著成果,但目前临床的抗病毒治疗只能抑制病毒的复制,尚不能彻底清除体内乙型肝炎病毒。病毒的耐药变异仍然是影响CHB抗病毒疗效的重要原因之一,现国际国内仍在探讨新的抗病毒治疗方法,特别是新的免疫治疗策略以期获得持久的病毒学和血清学应答,达到CHB的永久性治愈。本文就慢性乙型肝炎的抗病毒治疗最新进展进行综述。
Abstract:
The antiviral treatment of chronic hepatitis B is still a major problem at home and abroad. Although significant achievements have been made in recent years, the current clinical antiviral treatment can only inhibit the replication of the virus, and the hepatitis B virus in the body cannot be completely eliminated. . Virus resistance mutation is still one of the important reasons that affect the antiviral efficacy of CHB. New antiviral treatment methods are still being explored internationally and internationally, especially new immunotherapy strategies in order to obtain long-lasting virological and serological responses. A permanent cure for CHB. This article reviews the recent advances in antiviral therapy for chronic hepatitis B.

参考文献/References:


[1]中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南(2015年更新版)[J].临床肝胆病杂志,2015,31(12):1941-1960.
[2]Liaw YF,Kao JH,Piratvisuth T,et al.Asian-Pacific consensus statement on the management of chronic hepatitis B[J].Hepatol Int,2012,6(3):531-561.
[3]Papatheodoridis G,Buti M,Cornberg M,et al.EASL Clinical Practice Guidelines: management of chronic hepatitis B virus infection[J].J Hepatol,2012,57(1):167-185.
[4]Chan LY,Sang HA,Chang TT,et al.Peginterferon Lambda, a New Potential Therapeutic Option for the Treatment of Chronic Hepatitis B: A Phase 2B Comparison with Peginterferon Alfa in Patients with HBeAg-Positive Disease[J].Hepatology,2012,56(6):1525-1526.
[5]Tseng TC,Yu ML,Liu CJ,et al.Effect of host and viral factors on hepatitis B e antigen-positive chronic hepatitis B patients receiving pegylated interferonalpha-2a therapy[J].Antivir Ther,2011,16(5):629-637.
[6]Wu X,Xin Z,Zhu X,et al.Evaluation of susceptibility locus for response to interferon-alpha based therapy in chronic hepatitis B patients in Chinese[J].Antiviral Res,2012,93(2):297-300.
[7]Sonneveld MJ,Wong VW,Woltman AM,et al.Polymorphisms near IL28B and serologic response to peginterferon in HBeAg-positive patients with chronic Hepatitis B[J].Gastroenterology,2012,142(3):513-520.
[8]Lampertico P,Vigano M,Cheroni C,et al.IL28B polymorphisms predict interferon-related hepatitis B surface antigen seroclearance in genotype D hepatitis B e antigen-negative patients with chronic hepatitis B[J].Hepatology,2013,57(3):890-896.
[9]朱月永,吴银莲,陈靖,等.聚乙二醇干扰素α-2a治疗HBeAg阳性慢性乙型肝炎72周疗程的疗效优于常规疗程[J].中华肝脏病杂志,2012,20(10):737-741.
[10]曹振环,马丽娜,柳雅立,等.聚乙二醇干扰素α-2a联合阿德福韦酯治疗HBeAg阴性慢性乙型肝炎的临床研究[J].中华肝脏病杂志,2013,21(7):498-501.
[11]Lampertico P,Viganò M,Di Costanzo GG,et al.Randomised study comparing 48 and 96 weeks peginterferon α-2a therapy in genotype D HBeAg-negative chronic hepatitis B[J].Gut,2013,62(2):290-298.
[12]Liaw YF,Jia JD,Chan HL,et al.Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotype B or C[J].Hepatology,2011,54(5):1591-1599.
[13]Rijckborst V,Hansen BE,Ferenci P,et al.Validation of a stopping rule at week12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alpha-2a[J].J Hepatol,2012,56(5):1006-1011.
[14]Piratvisuth T,Marcellin P,Popescu M,et al.Hepatitis B surface antigen: association with sustained response to peginterferon alfa-2a in hepatitis B e antigen-positive patients[J].Hepatol Int,2013,7(2):429-436.
[15]Marcellin P,Bonino F,Yurdaydin C,et al.Hepatitis B surface antigen levels: association with 5-year response to peginterferon alfa-2a in hepatitis B e-antigen-negative patients[J].Hepatol Int,2013,7(1):88-97.
[16]Sonneveld MJ,Hansen BE,Piratvisuth T,et al.Response-guided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis B surface antigen levels[J].Hepatology,2013,58(3):872-880.
[17]Ono A,Suzuki F,Kawamura Y,et al.Long-term continuous entecavir therapy in nucleos(t)ide-naive chronic hepatitis B patients[J].J Hepatol,2012,57(3):508-514.
[18]Hou JL,Jia JD,Wei L,et al.Efficacy and safety of entecavir treatment in a heterogeneous CHB population from a 'real-world' clinical practice setting in China[J].J Viral Hepat,2013,20(11):811-820.
[19]Lok AS,Trinh H,Carosi G,et al.Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naive patients with chronic hepatitis B[J].Gastroenterology,2012,143(3):619-628.
[20]周一鸣,曹建彪,闻炜,等.乙型肝炎病毒变异后果及原因分析[J].胃肠病学和肝病学杂志,2011,20(11):1035-1037.
[21]Liaw YF,Gane E,Leung N,et al.2-Year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B[J].Gastroenterology,2009,136(2):486-495.
[22]Lai CL,Gane E,Liaw YF,et al.Telbivudine versus lamivudine in patients with chronic hepatitis B[J].N Engl J Med,2007,357(25):2576-2588.
[23]Han GR,Cao MK,Zhao W,et al.A prospective and open-label study for the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus infection[J].J Hepatol,2011,55(6):1215-1221.
[24]Gish RG,Clark MD,Kane SD,et al.Similar risk of renal events among patients treated with tenofovir or entecavir for chronic hepatitis B[J].Clin Gastroenterol Hepatol,2012,10(8):941-946.
[25]Marcellin P,Heathcote EJ,Buti M,et al.Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B[J].N Engl J Med,2008,359(23):2442-2455.
[26]Heathcote EJ,Marcellin P,Buti M,et al.Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B[J].Gastroenterology,2011,140(1):132-143.
[27]Brouwer WP,Xie Q,Sonneveld MJ,et al.Adding peginterferon to entecavir for HBeAg-positive chronic hepatitis B: A multicentre randomized trial (ARES study)[J].Hepatology,2015,61(5):1512-1522.
[28]Kittner JM,Sprinzl MF,Grambihler A,et al.Adding pegylated interferon to a current nucleos(t)ide therapy leads to HBsAg seroconversion in a subgroup of patients with chronic hepatitis B[J].J Clin Virol,2012,54(1):93-95.
[29]Ning Q,Han MF,Sun YT,et al.Switching from entecavir to Peg IFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: A randomised open-label trial (OSST trial)[J].J Hepatol,2014,61(4):777-784.
[30]Hu P,Jia S,Zhang WH,et al.A multi-center randomized study on the efficacy and safety of switching to peginterferonα-2a (40 KD)for 48 or 96 weeks in HBeAg positive CHB patients with a prior NUC history for 1 to 3 years: an interim analysis of NEW SWITCH study[J].Hepatology,2014,60(6):1273A-1274A.
[31]Ouzan D,Pénaranda G,Joly H,et al.Add-on peg-interferon leads to loss of HBsAg in patients with HBeAg-negative chronic hepatitis and HBV DNA fully suppressed by long-term nucleotide analogs[J].J Clin Virol,2013,58(4):713-717.
[32]Su WW,Hsu CW,Lee CM,et al.Combination therapy with peginterferon alfa-2a and a nucleos(t)ide analogue for HBeAg-positive chronic hepatitis B patients: results of a large randomized, multicentre, double-blind, placebo-controlled study[J].Journal of Hepatology,2014,60(1):S47.
[33]Petersen J,Ratziu V,Buti M,et al.Entecavir plus tenofovir combination as rescue therapy in pretreated chronic hepatitis B patients: an international multicenter cohort study[J].J Hepatol,2012,56(3):520-526.
[34]Seto WK,Liu K,Fung J,et al.Outcome of lamivudine-resistant chronic hepatitis B after up to 5 years of combination therapy with adefovir[J].Antivir Ther,2012,17(7):1255-1262.
[35]Zhao P,Wang C,Huang L,et al.Comparison of rescue strategies in lamivudine-resistant patients with chronic hepatitis B[J].Antiviral Res,2012,96(2):100-104.
[36]Sun J,Hou JL,Xie Q,et al.Randomised clinical trial:efficacy of peginterferon alfa-2a in HBeAg positive chronic hepatitis B patients with lamivudine resistance[J].Aliment Pharmacol Ther,2011,34(4):424-431.
[37]岳伟,袁宏,毛小荣,等.不同策略治疗rtN236T位点变异的HBeAg阳性慢性乙型肝炎的疗效观察[J].中华肝脏病杂志,2013,21(3):184-188.
[38]Reijnders JG,Perquin MJ,Zhang N,et al.Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B[J].Gastroenterology,2010,139(2):491-498.
[39]Tseng TC,Liu CJ,Su TH,et al.Young chronic hepatitis B patients with nucleos(t)ide analogue-induced hepatitis B e antigen seroconversion have a higher risk of HBV reactivation[J].J Infect Dis,2012,206(10):1521-1531.
[40]Bertoletti A,Ferrari C.Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection[J].Gut,2012,61(12):1754-1764.
[41]Boni C,Laccabue D,Lampertico P,et al.Restored function of HBV-specific T-cells after long-term effective therapy with nucleos(t)ide analogues[J].Gastroenterology,2012,143(4):963-973.
[42]Fisicaro P,Valdatta C,Massari M,et al.Combined blockade of programmed death-1 and activation of CD137 increase responses of human liver T-cells against HBV, but not HCV[J].Gastroenterology,2012,143(6):1576-1585.
[43]Ejrnaes M,Filippi CM,Martinic MM,et al.Resolution of a chronic viral infection after interleukin-10 receptor blockade[J].J Exp Med,2006,203(11):2461-2472.
[44]Tinoco R,Alcalde V,Yang Y,et al.Cell-intrinsic transforming growth factor-beta signaling mediates virus-specific CD8+ T cell deletion and viral persistence in vivo[J].Immunity,2009,31(1):145-157.
[45]Peppa D,Micco L,Javaid A,et al.Blockade of immunosuppressive cytokines restores NK cell antiviral function in chronic hepatitis B virus infection[J].PLoS Pathog,2010,6(12):e1001227.
[46]Akhurst RJ,Hata A.Targeting the TGFβ signalling pathway in disease[J].Nat Rev Drug Discov,2012,11(10):790-811.
[47]Manigold T,Racanelli V.T-cell regulation by CD4 regulatory T-cells during hepatitis B and C virus infections: facts and controversies[J].Lancet Infect Dis,2007,7(12):804-813.
[48]Bertoletti A,Gehring A.Therapeutic vaccination and novel strategies to treat chronic HBV infection[J].Expert Rev Gastroenterol Hepatol,2009,3(5):561-569.
[49]Lok AS,Pan CQ,Han SH,et al.Randomized phase Ⅱ study of GS-4774 as a therapeutic vaccine in virally suppressed patients with chronic hepatitis B[J].J Hepatol,2016,65(3):509-516.
[50]陆建国.聚乙二醇干扰素α-2a联合乙肝疫苗治疗慢性乙型肝炎疗效观察[J].实用肝脏病杂志,2014,17(1):34-36.
[51]Wooddell CI,Rozema DB,Hossbach M,et al.Hepatocyte-targeted RNAi therapeutics for the treatment of chronic hepatitis B virus infection[J].Mol Ther,2013,21(5):973-985.

相似文献/References:

[1]林晓岚,郑丽花,陈苑莉,等.微信随访对慢性乙型肝炎患者抗病毒治疗效果和 生活质量的影响研究[J].医学信息,2018,(10):164.[doi:10.3969/j.issn.1006-1959.2018.10.057]
 LIN Xiao-lan,ZHENG Li-hua,CHEN Yuan-li,et al.Effect of WeChat Follow-up on Antiviral Treatment and Quality of Life in Patients with Chronic Hepatitis B[J].Medical Information,2018,(04):164.[doi:10.3969/j.issn.1006-1959.2018.10.057]
[2]林晓岚,陈苑莉.慢性乙型肝炎患者治疗依从性及其对生活质量的影响[J].医学信息,2018,(13):168.[doi:10.3969/j.issn.1006-1959.2018.13.052]
 LIN Xiao-lan,CHEN Yuan-li.Treatment Compliance of Patients with Chronic Hepatitis B and its Influence on Quality of Life[J].Medical Information,2018,(04):168.[doi:10.3969/j.issn.1006-1959.2018.13.052]
[3]吴 刚,吴锦瑜.HBeAg阴性慢性乙型肝炎患者血清25-羟基维生素D3的 检测及临床意义[J].医学信息,2018,(19):96.[doi:10.3969/j.issn.1006-1959.2018.19.028]
 WU Gang,WU Jin-yu.Detection and Clinical Significance of Serum 25-hydroxyvitamin D3 in Patients with HBeAg-negative Chronic Hepatitis B[J].Medical Information,2018,(04):96.[doi:10.3969/j.issn.1006-1959.2018.19.028]
[4]叶向荣.恩替卡韦治疗慢性乙型肝炎病毒感染的临床价值评价[J].医学信息,2018,(22):147.[doi:10.3969/j.issn.1006-1959.2018.22.043]
 YE Xiang-rong.Clinical Evaluation of Entecavir in Treatment of Patients with Chronic Hepatitis B Virus Infection[J].Medical Information,2018,(04):147.[doi:10.3969/j.issn.1006-1959.2018.22.043]
[5]马 琳,田瑞民.乙型病毒性肝炎相关晚期肝病的抗病毒治疗效果观察[J].医学信息,2019,(07):120.[doi:10.3969/j.issn.1006-1959.2019.07.036]
 MA Lin,TIAN Rui-min.Observation on the Effect of Antiviral Therapy For Advanced Hepatopathy Associated with Viral Hepatitis B[J].Medical Information,2019,(04):120.[doi:10.3969/j.issn.1006-1959.2019.07.036]

更新日期/Last Update: 2019-03-07